Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth in revenue and profitability.

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Medical device company ResMed (NYSE:RMD) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

If you’re feeling unprepared for potential outages, you can pick up a Bluetti portable power station at a major discount, ...

CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...

Truck drivers – particularly independent drivers, face significant health challenges on the road. But modern technology can help drivers be healthier, says Lisa Paul, CPCU, chief strategy officer, ...

Understand the significant growth trajectory of the Disease Diagnosis Application segment, which is expected to reach $89.4 ...

Needham analyst Michael Matson has maintained their neutral stance on RMD stock, giving a Hold rating on January 29.Invest with Confidence: ...

RBC Capital analyst Craig Wong-Pan maintained a Hold rating on Resmed (RMD – Research Report) on January 29 and set a price target of $238.00.